EWING SARCOMA

This early-phase study tests a new drug, DXC008, for safety and the right dose in people with prostate cancer or other solid tumors like Ewing sarcoma that have not responded to standard treatments. About 110 adults aged 18 to 75 will take part. The goal is to find out if the dru…

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with solid tumors, especially Ewing sarcoma that has returned or not responded to prior treatment. The first part finds the safest dose, and the second part checks how well the drug shrinks t…

This study tests an experimental oral drug called AMXT 1501 combined with another drug, eflornithine (DFMO), in children and young adults up to age 21 with certain cancers like neuroblastoma, brain tumors, and sarcomas. The goal is to find the best dose and see if the combination…

This study tests whether combining two drugs, pembrolizumab and cabozantinib, can stop or shrink advanced sarcomas (soft tissue and bone cancers). About 119 adults whose cancer has worsened after standard treatment will take part. The main goal is to see how many patients have no…

This early-phase study tests an experimental oral drug, ST-01156, in adults with advanced solid tumors (including Ewing sarcoma, liver, and bile duct cancers) that have spread or cannot be removed. The main goals are to find a safe dose and understand side effects. Participants t…

This early-stage study tests whether a new treatment combining radiation and specially engineered immune cells (B7-H3-CAR T cells) is safe for children and young adults up to age 21 with sarcomas that have returned or not responded to standard therapy. The treatment aims to help …

This early-phase study tests a stem cell transplant from a half-matched donor for children with blood cancers or solid tumors that have come back or are hard to treat. The transplant uses a special method to remove certain immune cells, and patients also receive a drug called zol…

This early-stage trial tests a new drug called INBRX-109, a lab-made antibody designed to target and kill cancer cells. It is for people with advanced solid tumors, including a type of bone cancer called Ewing sarcoma, that have not responded to other treatments. The main goals a…

This early-stage study tests whether a combination of specially engineered immune cells (HER2-CAR T cells) and an immune-boosting drug (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion t…

This study tests a drug called lurbinectedin in people aged 10 and older with certain sarcomas (like Ewing sarcoma) that have come back after treatment. The goal is to see if the drug is safe and can shrink tumors or delay their growth. Participants must have a specific genetic c…

This early-stage study tests a treatment where a child's own immune cells are collected, modified to better recognize and attack certain solid tumors, and then given back as a one-time infusion. The main goal is to find the safest dose and see if it can shrink tumors. The study i…

This study is for children, teens, and young adults up to age 39 with sarcoma that has spread to a few spots in the body. The goal is to see if giving focused radiation to those spread sites, along with standard treatment, can help them live longer without the cancer getting wors…

This study looks at how well people with bone cancer follow a personalized exercise program at home after having surgery on their leg. Researchers will track daily exercise habits for six months and look for factors that help or hinder adherence. The goal is to improve rehabilita…

This study is testing whether a blood test (liquid biopsy) can help doctors predict the future course of Ewing sarcoma and osteosarcoma in children and young adults. Researchers will look for tumor DNA in the blood at diagnosis and see if it relates to how well patients do over t…